Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

View:
Post by zebTrader on Dec 08, 2017 11:28am

Why +7% today?

Any information why today we have +7%? I find no news that would explain this. At least the volume is quite high!
Comment by AlwaysBullishhh on Dec 08, 2017 12:54pm
Maybe they will have something positive to announce. https://ir.valeant.com/news-releases/2016/11-10-2016-133248999
Comment by AlwaysBullishhh on Dec 08, 2017 12:58pm
oups, wrong link https://ir.valeant.com/news-releases/2017/12-07-2017-130227641
Comment by zebTrader on Dec 08, 2017 1:34pm
Thank you for the link - I noticed that the conference has not started yet. A lot of people already know but we are in dark.  I'm pleased but eager to know what is going on. Its close to +11% now, nice! Volume is huge.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities